Press releases

The DSMB* considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The...

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...

The first stage of the Phase II clinical trial continues despite the COVID-19 pandemic in the U.S New development contract signed with DSM...

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected in Q4 2021 Strengthening of...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

This new agreement with European Select Growth Opportunities Fund enables the issuance of notes convertible into new shares for a maximum...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

Co-funded by the European Fund FEDER DEINOVE is intensifying its collaboration with the Max Mousseron Institute of Biomolecules (IBMM) and...

The Extraordinary Shareholders’ Meeting will be convened on third notice at a later date DEINOVE (Euronext Growth Paris: ALDEI), a French...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...